Parnell Pharmaceuticals Holdings Ltd banner

Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF

Watchlist Manager
Parnell Pharmaceuticals Holdings Ltd Logo
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Watchlist
Price: 0.08 USD Market Closed
Market Cap: $1.4m

Relative Value

PARNF latest financial reports are more than 6 years old.
PARNF doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of PARNF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PARNF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PARNF Competitors Multiples
Parnell Pharmaceuticals Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
1.4m USD 0.1 -0.1 -0.4 -0.4
US
Eli Lilly and Co
NYSE:LLY
923.3B USD 14.2 44.7 30.2 32.2
US
Johnson & Johnson
NYSE:JNJ
582.8B USD 6.2 21.7 15.1 18.6
CH
Roche Holding AG
SIX:ROG
253.4B CHF 4.1 19.6 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
223.5B GBP 5.1 29.3 16.2 22.9
CH
Novartis AG
SIX:NOVN
231.8B CHF 5.3 21.4 13.2 17
US
Merck & Co Inc
NYSE:MRK
286.8B USD 4.4 15.7 9.8 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
152.7B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118.7B USD 2.5 16.8 7.1 8.8
P/E Multiple
Earnings Growth PEG
AU
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Average P/E: 22.2
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
CH
Novartis AG
SIX:NOVN
21.4
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Average EV/EBITDA: 46.4
Negative Multiple: -0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.2
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
CH
Novartis AG
SIX:NOVN
13.2
5%
2.6
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Average EV/EBIT: 100.9
Negative Multiple: -0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.6
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
CH
Novartis AG
SIX:NOVN
17
9%
1.9
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
3%
3.1
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett